UK bans the first ads for oral weight-loss pills — one ran before the drug existed

Ads for oral weight-loss medicines have been banned in the UK for the first time. The Advertising Standards Authority ruled against online pharmacies Simple Online Pharmacy and Pharmacy Online, which had advertised oral GLP-1 treatments through social media ads and their websites — including inviting people to join waiting lists, register interest and pre-order treatment. Three further rulings followed against MedExpress, Juniper and the Care Pharmacy for promoting prescription-only medicines to the public even without naming any product.

The Simple Online Pharmacy ad, seen on June 1, promoted oral GLP-1 treatments before any such medicine had been authorised in the UK — it invited people to 'join the waitlist' for a new oral weight-management treatment, and the first oral GLP-1 tablet was only licensed as prescription-only on June 11. Medicines must be authorised by the MHRA before promotion, and once licensed as prescription-only they cannot be advertised to the public. Pharmacy Online's banned ads — a 'pre-order' pop-up for the oral Wegovy tablet plus paid social ads — ran after licensing and broke that line.

The ASA called the rulings part of wider action against irresponsible weight-loss ads and warned advertisers to weigh an ad's overall impression: its research found people did not need a named product to know an ad was selling weight-loss medication. Catherine Drewett, the ASA's investigations manager, said the licensing of oral GLP-1s brings 'new challenges for regulators' and makes clear these oral medicines, like the injections, cannot be advertised to the public. MHRA's Julian Beach agreed: 'Stimulating consumer demand for a new prescription medicine is not permitted.'

The waitlist mechanic treated an unlicensed medicine as a consumer product — building demand for a pill that had no UK marketing authorisation when the ad ran.

Pre-order pop-ups after licensing made the same mistake one step later: prescription-only means never advertised to the public, however it is dressed up.

The three rulings against unnamed-product ads show regulators judge the overall impression, not technicalities — 'people did not need to see a named product'.

The ASA signalled continued monitoring with the MHRA and GPhC, so the rulings are the start of enforcement, not a one-off.

A new drug format is not a new rule: prescription-only status follows the molecule into pills, and 'join the waitlist' is promotion too — regulators judge the impression, not the fine print.

The ASA said it would continue to monitor ads and emerging trends for the medications, working closely with the MHRA and the General Pharmaceutical Council. The material reports no penalties beyond the bans.